Physician profile
John M Ravits
NPI 1396858965
$12,815.08
in general payments reported to CMS, 2019-2025
12 companies · $4,278 in 2025
The $4,278 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,935 · 2020: $3,675 · 2022: $127 · 2024: $1,800 · 2025: $4,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,250 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800 · Food and Beverage: $28.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
| Food and Beverage | $28.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novavax INC | $4,250.00 | 2025 | Novavax Covid-19 Vaccine, Adjuvanted |
| Biogen, INC. | $3,801.90 | 2020-2022 | |
| Genentech, INC. | $1,800.00 | 2024 | |
| Tanabe Pharma America, INC. | $1,650.00 | 2019 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $1,187.00 | 2019 | |
| Edw Pharma, INC. | $79.87 | 2019 | |
| Ionis Pharmaceuticals, INC. | $28.42 | 2025 | |
| Neurocrine Biosciences, INC. | $17.89 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ravits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.